You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 19, 2025

Details for Patent: 10,292,954


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,292,954 protect, and when does it expire?

Patent 10,292,954 protects SOHONOS and is included in one NDA.

This patent has thirty-one patent family members in nineteen countries.

Summary for Patent: 10,292,954
Title:Composition and method for muscle repair and regeneration
Abstract:The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
Inventor(s):Masahiro Iwamoto, Maurizio Pacifici
Assignee:Thomas Jefferson University
Application Number:US15/674,357
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,292,954: A Comprehensive Guide

Introduction

When analyzing a patent, understanding its scope, claims, and the broader patent landscape is crucial for inventors, patent holders, and legal professionals. This article will delve into the specifics of United States Patent 10,292,954, although the exact details of this patent are not provided in the sources. We will, however, use general principles and examples to illustrate how to conduct such an analysis.

Understanding Patent Claims

Patent claims are the heart of a patent, defining the scope of the invention for which protection is sought. They must be clear, concise, and supported by the patent's specification[4].

Types of Claims

  • Independent Claims: These stand alone and define the invention without reference to other claims.
  • Dependent Claims: These refer back to and further limit an independent claim.
  • Method Claims: Describe a process or method.
  • Apparatus Claims: Describe a physical device or system.
  • Composition Claims: Describe a chemical or biological composition.

Patent Scope and Coverage

The scope of a patent is determined by its claims. Here are some key points to consider:

Novelty Requirement

For a patent to be granted, the claimed invention must be novel, meaning it must not have been patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention[4].

Nonobviousness Requirement

The invention must also be nonobvious, meaning it must be significantly different from existing technology and not obvious to a person of ordinary skill in the relevant field[4].

Written Description and Enablement

The patent specification must contain a written description of the invention and enable a person of ordinary skill in the art to make and use the invention[4].

Patent Term Adjustments (PTA) and Extensions

Patent term adjustments and extensions can affect the scope and duration of patent protection.

Patent Term Adjustment (PTA)

PTA is granted to compensate for delays in the patent prosecution process. For example, if the USPTO fails to respond promptly to an application, the patent term may be extended by one day for each day of delay[1].

Patent Term Extension (PTE)

PTE, on the other hand, is typically granted due to regulatory delays, such as those related to FDA approval. However, a terminal disclaimer, which is often used to overcome obviousness-type double patenting (ODP) rejections, does not extend the patent term past the date of the terminal disclaimer[1].

Obviousness-Type Double Patenting (ODP)

ODP is a doctrine that prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to a grant of PTA or other adjustments[1].

The Patent Landscape

Understanding the broader patent landscape involves analyzing existing patents, patent applications, and trends in the field.

Patent Claims Research Dataset

The USPTO provides datasets that contain detailed information on claims from U.S. patents granted between 1976 and 2014 and U.S. patent applications published between 2001 and 2014. These datasets can help in identifying trends and patterns in patent claims and scope[3].

GATT Bubble and Its Impact

The GATT Bubble, which occurred in the mid-1990s, saw a significant influx of patent applications due to changes in patent term lengths. This period is instructive in understanding how bulk filings and extensive claim sets can impact patent prosecution and the patent landscape[2].

Legal and Regulatory Framework

The U.S. patent system is governed by statutes and regulations, notably the Leahy-Smith America Invents Act (AIA) of 2011.

America Invents Act (AIA)

The AIA introduced significant changes, including the transition from a first-to-invent to a first-to-file system and the creation of new post-grant review procedures like Inter Partes Review (IPR)[4].

Case Law and Precedents

Court decisions play a crucial role in shaping the interpretation of patent laws and regulations.

Hyatt v. Hirshfeld

This case highlights issues related to prosecution laches, anticipation, and written description. It also illustrates the challenges of managing large numbers of claims and the importance of focusing claims on distinct subject matter[2].

In re Cellect

This case addresses ODP and the impact of terminal disclaimers on patent term adjustments, emphasizing the need for careful analysis of patent term extensions and disclaimers[1].

Key Takeaways

  • Clear and Concise Claims: Ensure that patent claims are clear, concise, and supported by the specification.
  • Novelty and Nonobviousness: The invention must meet the novelty and nonobviousness requirements.
  • Patent Term Adjustments: Understand how PTA and PTE can affect the duration of patent protection.
  • ODP Analysis: Be aware of the implications of ODP and how terminal disclaimers can impact patent term.
  • Patent Landscape Analysis: Use datasets and case law to understand trends and potential challenges in the patent landscape.

FAQs

  1. What is the difference between Patent Term Adjustment (PTA) and Patent Term Extension (PTE)?

    • PTA is granted to compensate for delays in the patent prosecution process, while PTE is typically granted due to regulatory delays.
  2. How does Obviousness-Type Double Patenting (ODP) affect patent claims?

    • ODP prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term.
  3. What is the significance of the GATT Bubble in patent law?

    • The GATT Bubble led to a significant influx of patent applications, highlighting challenges in managing bulk filings and extensive claim sets.
  4. How does the Leahy-Smith America Invents Act (AIA) impact patent law?

    • The AIA introduced a first-to-file system, new post-grant review procedures, and other significant changes to the U.S. patent system.
  5. Why is it important to analyze the patent landscape?

    • Analyzing the patent landscape helps in identifying trends, potential challenges, and existing patents, which is crucial for strategic patent filing and enforcement.

Sources

  1. In re Cellect - United States Court of Appeals for the Federal Circuit[1].
  2. Hyatt v. Hirshfeld - Court of Appeals for the Federal Circuit[2].
  3. Patent Claims Research Dataset - USPTO[3].
  4. The Patent Trial and Appeal Board and Inter Partes Review - Congressional Research Service[4].

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,292,954

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-001 Aug 16, 2023 RX Yes No 10,292,954 ⤷  Try for Free REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Try for Free
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-002 Aug 16, 2023 RX Yes No 10,292,954 ⤷  Try for Free REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Try for Free
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-003 Aug 16, 2023 RX Yes No 10,292,954 ⤷  Try for Free REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Try for Free
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-004 Aug 16, 2023 RX Yes No 10,292,954 ⤷  Try for Free REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Try for Free
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-005 Aug 16, 2023 RX Yes Yes 10,292,954 ⤷  Try for Free REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,292,954

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011296080 ⤷  Try for Free
Brazil 112013004685 ⤷  Try for Free
Canada 2809374 ⤷  Try for Free
Chile 2013000580 ⤷  Try for Free
China 103200937 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.